Perrigo Extended-Release Acetaminophen Launch Delayed By QC Issues
This article was originally published in The Tan Sheet
Executive Summary
Perrigo has postponed its plans to market private label extended-release acetaminophen until it can resolve quality control issues outlined in a recent FDA warning letter.
You may also be interested in...
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth